Although HOXD10 and its targets failed to show a significant correlation with PFS, we indeed observed a trend that patients with low expressions of HOXD10, miR-7, and IGFBP3 had poor prognosis (Figure 5C), suggesting that the activation of HOXD10 and its targets may increase chemosensitivity to 5-FU in CRC. The gene discussed is HOXD10; the disease is colorectal carcinoma.